StockData
Merck & Co., Inc. logo

Merck & Co., Inc.

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30250% above fair value
$149.52+3.19 (+2.18%)

Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%

Merck Primaxin (imipenem and cilastatin, legacy) by Quarter

Primaxin (imipenem and cilastatin, legacy) — U.S. sales ($M) ($M)

QuarterlyAnnual

Merck Primaxin (imipenem and cilastatin, legacy): -$1M in Q4 2023. No newer figure appears in the documents we track.

Latest, Q4 2023
-1
Period ended Dec 31, 2023
Change on a year earlier
–
0 in Q4 2022
History
29 quarters
Since Q4 2016
Sources
21
Documents cited below

Where the Q4 2023 figure comes from

Calculated from reported figures: Q4 = full year (10-K) − nine months (10-Q)

Source: Form 10-K (filed 2024-02-26) ↗

Reported in Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedPrimaxin (imipenem and cilastatin, legacy) — U.S. sales ($M) ($M)Year on yearSource
Q4 2023Dec 31, 2023-1–Form 10-K (filed 2024-02-26) ↗
Q3 2023Sep 30, 20230–Form 10-Q (filed 2023-11-03) ↗
Q2 2023Jun 30, 2023-2–Form 10-Q (filed 2023-08-07) ↗
Q1 2023Mar 31, 20234+300.0%Form 10-Q (filed 2023-05-05) ↗
Q4 2022Dec 31, 20220-100.0%Form 10-K (filed 2024-02-26) ↗
Q3 2022Sep 30, 20220–Form 10-Q (filed 2023-11-03) ↗
Q2 2022Jun 30, 20220–Form 10-Q (filed 2023-08-07) ↗
Q1 2022Mar 31, 20221–Form 10-Q (filed 2023-05-05) ↗
Q4 2021Dec 31, 20212–Form 10-K (filed 2024-02-26) ↗
Q3 2021Sep 30, 20210-100.0%Form 10-Q (filed 2022-11-03) ↗
Q2 2021Jun 30, 20210-100.0%Form 10-Q (filed 2022-08-05) ↗
Q1 2021Mar 31, 20210–Form 10-Q (filed 2022-05-05) ↗
Q4 2020Dec 31, 20200–Form 10-K (filed 2023-02-24) ↗
Q3 2020Sep 30, 20201-50.0%Form 8-K (tm2032785d1_ex99-1.htm, filed 2020-10-27) ↗
Q2 2020Jun 30, 20201–Form 10-Q (filed 2021-08-09) ↗
Q1 2020Mar 31, 20200–Form 10-Q (filed 2021-05-05) ↗

Cite this data

StockData. (2026). Merck Primaxin (imipenem and cilastatin, legacy) ($M), quarterly Q4 2016–Q4 2023 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-primaxin-us

See every metric in the Merck KPI table. Data updated Oct 26, 2026.